Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Vis Exp ; (83): e51161, 2014 01 29.
Artigo em Inglês | MEDLINE | ID: mdl-24514151

RESUMO

Antibodies against red blood cells (RBCs) can lead to complement activation resulting in an accelerated clearance via complement receptors in the liver (extravascular hemolysis) or leading to intravascular lysis of RBCs. Alloantibodies (e.g. ABO) or autoantibodies to RBC antigens (as seen in autoimmune hemolytic anemia, AIHA) leading to complement activation are potentially harmful and can be - especially when leading to intravascular lysis - fatal(1). Currently, complement activation due to (auto)-antibodies on RBCs is assessed in vitro by using the Coombs test reflecting complement deposition on RBC or by a nonquantitative hemolytic assay reflecting RBC lysis(1-4). However, to assess the efficacy of complement inhibitors, it is mandatory to have quantitative techniques. Here we describe two such techniques. First, an assay to detect C3 and C4 deposition on red blood cells that is induced by antibodies in patient serum is presented. For this, FACS analysis is used with fluorescently labeled anti-C3 or anti-C4 antibodies. Next, a quantitative hemolytic assay is described. In this assay, complement-mediated hemolysis induced by patient serum is measured making use of spectrophotometric detection of the released hemoglobin. Both of these assays are very reproducible and quantitative, facilitating studies of antibody-induced complement activation.


Assuntos
Anemia Hemolítica Autoimune/imunologia , Ativação do Complemento/imunologia , Complemento C3/imunologia , Complemento C4/imunologia , Eritrócitos/imunologia , Anemia Hemolítica Autoimune/sangue , Bromelaínas/farmacologia , Proteína Inibidora do Complemento C1/farmacologia , Eritrócitos/química , Eritrócitos/efeitos dos fármacos , Hemólise/imunologia , Humanos
2.
Acta Crystallogr D Biol Crystallogr ; 68(Pt 7): 794-9, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22751664

RESUMO

Potato serine protease inhibitor (PSPI) constitutes about 22% of the total amount of proteins in potato tubers (cv. Elkana), making it the most abundant protease inhibitor in the plant. PSPI is a heterodimeric double-headed Kunitz-type serine protease inhibitor that can tightly and simultaneously bind two serine proteases by mimicking the substrate of the enzyme with its reactive-site loops. Here, the crystal structure of PSPI is reported, representing the first heterodimeric double-headed Kunitz-type serine protease inhibitor structure to be determined. PSPI has a ß-trefoil fold and, based on the structure, two reactive-site loops bearing residues Phe75 and Lys95 were identified.


Assuntos
Proteínas de Plantas/química , Inibidores de Serina Proteinase/química , Solanum tuberosum/química , Sequência de Aminoácidos , Domínio Catalítico , Cristalografia por Raios X , Modelos Moleculares , Dados de Sequência Molecular , Estrutura Secundária de Proteína , Alinhamento de Sequência , Inibidores de Serina Proteinase/isolamento & purificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA